ClinicalTrials.gg
CompletedNCT01954615Updated Jul 10, 2018

Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

A Phase 1 interventional study of 5 mg ACT-281959 prodrug formulation I (Group A) and 20 mg ACT-281959 prodrug formulation I (Group B) in Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in France. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Study Part I is a single-ascending dose study. Healthy male subjects to be included in the study and randomized in 6 dose groups, Groups A-F (8 subjects per group). Of the 8 subjects per group, 6 subjects receive the investigational drug and 2 subjects receive matching placebo. Study Part II is a 3-period, crossover, single dose study. Nine healthy male subjects to be enrolled in one group (Group G). Each subject to receive 2 different formulations of the prodrug and one formulation of the active drug in a randomized sequence.

Read the detailed description

Study Part I is a prospective, single-center, double-blind, randomized, placebo-controlled, single-ascending dose, Phase 1 study. Approximately 48 healthy male subjects to be included in the study and randomized in 6 dose groups, Groups A-F (8 subjects per group). Of the 8 subjects per group, 6 subjects are to receive the investigational drug and 2 subjects to receive matching placebo. Study Part II is a prospective, single-center, open-label, randomized, 3-period, crossover, single dose, Phase 1 study. Nine healthy male subjects to be enrolled in one group, Group G. Each subject to receive 2 different formulations of the prodrug and one formulation of the active drug in a randomized sequence.

02

Conditions studied

  • Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Keywords

  • ACT-281959
  • ACT-246475
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in the local language prior to any study-mandated procedure.
  • Healthy male subjects aged between 18 and 45 years (inclusive) at screening.
  • No findings on the physical examination at screening.
  • of 18.0 to 28.0 kg/m\^2 (inclusive) at screening.
  • Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 45-90 beats per minute (inclusive), measured on the dominant arm, after 5 minutes in the supine position at screening.
  • 12-lead without clinically relevant abnormalities, measured after 5 minutes in the supine position at screening.
  • Hematology, coagulation, clinical chemistry, and urinalysis test results not deviating to a clinically relevant extent from the normal range at screening.
  • Negative results from urine drug screen at screening.
  • Baseline value for maximal (at peak) aggregation ≥ 50% light transmission aggregometry upon 20 μM adenosine diphosphate (ADP) activation at screening.
  • Baseline values of closure time tested with the platelet function analyser 100, for both cartridges Collagen/Epinephrine and Collagen/ADP below the .
  • Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Known allergic reactions or to any of the drug formulation(s).
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition which would interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy and herniotomy were allowed, while cholecystectomy was not allowed).
  • Previous history of fainting, collapse, orthostatic hypotension, or vasovagal reactions.
  • Family or personal history of bleeding (e.g., stroke, major trauma, or surgical intervention), or bleeding disorders (e.g., thrombocytopenia, clotting disturbances, intracranial vascular diseases, peptic ulcers), or reasonable suspicion of vascular malformations.
  • count ˂ 120x10\^9/L at screening.
  • Veins unsuitable for intravenous puncture on either arm (e.g., veins that were difficult to locate, access, or puncture, veins with a tendency to rupture during or after puncture).
  • Treatment with another drug within 3 months prior to screening or participation in more than four investigational drug studies within 1 year prior to screening.
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
  • Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.
  • Smoking within 3 months prior to screening and inability to refrain from smoking during the course of the study.
  • Previous treatment with any prescribed or over-the-counter medications (including herbal medicines such as St. John's Wort) especially acetyl salicylic acid, non-steroidal anti-inflammatory, or any anticoagulant medication (e.g., heparin, warfarin), within 2 weeks prior to (the first) administration of study drug.
  • Loss of 250 mL or more of blood within 3 months prior to screening.
  • Positive results from the hepatitis serology, except for vaccinated subjects or subjects with past but resolved hepatitis, at screening.
  • Positive results from the serology at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, would affect full participation in the study or compliance with the protocol.
  • Legal incapacity or limited legal capacity at screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Group A 5 mg ACT-281959 prodrug formulation I/placebo

    6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.

    Drug: 5 mg ACT-281959 prodrug formulation I (Group A) · Drug: Placebo (Groups A to F)

  • Experimental
    Group B 20 mg ACT-281959 prodrug formulation I/placebo

    6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.

    Drug: 20 mg ACT-281959 prodrug formulation I (Group B) · Drug: Placebo (Groups A to F)

  • Experimental
    Group C ACT-281959 prodrug formulation I/placebo

    Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.

    Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined) · Drug: Placebo (Groups A to F)

  • Experimental
    Group D ACT-281959 prodrug formulation I/placebo

    6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.

    Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined) · Drug: Placebo (Groups A to F)

  • Experimental
    Group E ACT-281959 prodrug formulation I/placebo

    6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.

    Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined) · Drug: Placebo (Groups A to F)

  • Experimental
    Group F ACT-281959 prodrug formulation I/placebo

    Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.

    Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined) · Drug: Placebo (Groups A to F)

  • Experimental
    Group G ACT-281959 prodrug formulation I & II/ACT-246475

    9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.

    Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined) · Drug: ACT-281959 prodrug formulation II (Group G dose to be defined) · Drug: ACT-246475 (Group G dose to be defined)

Interventions

  • Drug5 mg ACT-281959 prodrug formulation I (Group A)
  • Drug20 mg ACT-281959 prodrug formulation I (Group B)
  • DrugACT-281959 prodrug formulation I (Groups C to G doses to be defined)
  • DrugACT-281959 prodrug formulation II (Group G dose to be defined)
  • DrugPlacebo (Groups A to F)
06

What researchers measure

Primary outcomes

  1. Change in supine systolic blood pressure from baseline up to the end of study

    Blood pressure to be measured using an automatic oscillometric device. Measurements to be taken with the subject in the supine position after a resting period of at least 5 min. The dominant (writing) arm will be used for all measurements. Measurements to be taken at 1, 2, 4, 8, 24, 48, and 72 hours post-dose.

    Time frame: 72 hours

  2. Change in supine diastolic blood pressure from baseline up to the end of study

    Blood pressure to be measured using an automatic oscillometric device. Measurements to be taken with the subject in the supine position after a resting period of at least 5 min. The dominant (writing) arm will be used for all measurements. Measurements to be taken at 1, 2, 4, 8, 24, 48, and 72 hours post-dose.

    Time frame: 72 hours

  3. Change in supine pulse rate from baseline up to the end of study

    Pulse rate to be measured using an automatic oscillometric device. Measurements to be taken with the subject in the supine position after a resting period of at least 5 min. The dominant (writing) arm will be used for all measurements. Measurements to be taken at 1, 2, 4, 8, 24, 48, and 72 hours post-dose.

    Time frame: 72 hours

  4. Change in body weight from baseline up to the end of study

    Body weight will be measured using the same weighing scale for all subjects and throughout the study. The weighing scale should have a precision of at least 0.5 kg.

    Time frame: 72 hours

  5. Change in PQ Interval from baseline up to the end of study

    A standard 12-lead electrocardiogram (ECG) will be recorded in supine position after a 5-min rest period. The PQ interval is the time interval from the beginning of the P wave to the beginning of the QRS complex. Measurements to be taken at 1, 2, 4, 8, 24, 48 and 72 hours post-dose.

    Time frame: 72 hours

  6. Change in QRS Interval from baseline up to the end of study

    A standard 12-lead electrocardiogram (ECG) will be recorded in supine position after a 5-min rest period. The QRS interval is the time interval from the beginning of the Q wave to the end of the S wave.Measurements to be taken at 1, 2, 4, 8, 24, 48 and 72 hours post-dose.

    Time frame: 72 hours

  7. Change in QT Interval from baseline up to the end of study

    A standard 12-lead electrocardiogram (ECG) will be recorded in supine position after a 5-min rest period. The QT interval is the time interval from beginning of the Q wave until end of the T wave. Measurements to be taken at 1, 2, 4, 8, 24, 48 and 72 hours post-dose.

    Time frame: 72 hours

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of ACT-246475

    Blood samples for pharmacokinetic analysis taken immediately prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours, after dosing. Cmax calculated on the basis of the blood sampling time points.

    Time frame: 72 hours

  2. Time to reach maximum plasma concentration (tmax) of ACT-246475

    Blood samples for pharmacokinetic analysis taken immediately prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours, after dosing. tmax calculated on the basis of the blood sampling time points.

    Time frame: 72 hours

  3. Area under the plasma concentration-time curve (AUC) from time 0 to time t of the last measured concentration (AUC0-t) of ACT-246475

    Blood samples for pharmacokinetic analysis taken immediately prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours, after dosing. AUC0-t calculated on the basis of the blood sampling time points, according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification.

    Time frame: 72 hours

  4. AUC from time zero to infinity (AUC0-∞) of ACT-246475

    Blood samples for pharmacokinetic analysis taken immediately prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours, after dosing. AUC0-∞ was calculated by combining AUC0-t and AUCextra. AUCextra is an extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration measured above the limit of quantification and λz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations in the terminal elimination phase.

    Time frame: 72 hours

  5. Terminal half-life (t1/2) of ACT-246475

    Blood samples for pharmacokinetic analysis taken immediately prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours, after dosing. t1/2 calculated on the basis of the blood sampling time points.

    Time frame: 72 hours

  6. Percentage inhibition of platelet aggregation following administration of ACT-281959 as prodrug formulation I

    Adenosine diphosphate(ADP)-induced platelet aggregation will be measured using 2 different assays: Light transmission aggregometry (20 μM ADP) and VerifyNow P2Y12 (ADP receptor) assays Blood samples taken prior to dosing and at 1, 2, 3, 4, 8, 12 and 24 hours post-dosing.

    Time frame: 24 hours

  7. Percentage inhibition of platelet aggregation following administration of ACT-281959 as prodrug formulation II

    Adenosine diphosphate(ADP)-induced platelet aggregation will be measured using 2 different assays: Light transmission aggregometry (20 μM ADP) and VerifyNow P2Y12 (ADP receptor) assays Blood samples taken prior to dosing and at 1, 2, 3, 4, 8, 12 and 24 hours post-dosing.

    Time frame: 24 hours

  8. Percentage inhibition of platelet aggregation following administration of ACT-246475

    Adenosine diphosphate(ADP)-induced platelet aggregation will be measured using 2 different assays: Light transmission aggregometry (20 μM ADP) and VerifyNow P2Y12 (ADP receptor) assays Blood samples taken prior to dosing and at 1, 2, 3, 4, 8, 12 and 24 hours post-dosing.

    Time frame: 24 hours

07

Study locations

1 site
  • Biotrial
    Rennes, 35000, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2013
First posted
Oct 7, 2013
Start
Oct 2011
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Last update
Jul 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01954615
Responsible party
Sponsor
First posted
Oct 7, 2013
Start date
Oct 2011
Primary completion
Mar 2012
Completion
Mar 2012
Last update
Jul 10, 2018

Study contacts

Daniela Baldoni, PharmD PhD
study director · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selatogrel

Start the discussion